Amplia Therapeutics Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
Amplia Therapeutics Limited, a pharmaceutical company, engages in the development of focal adhesion kinase (FAK) inhibitors in Australia. The company is developing inhibiting drug candidates, including AMP886 and AMP945 for oncology and chronic fibrosis indications. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
1.88
Dividend yield
Beta
0.42
Market cap
$22.47M
Enterprise value
$18.67M
Company profile
| Primary activities | Pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. |
|---|---|
| Industry / Sector | Biotechnology / Healthcare |
| Website | http://www.ampliatx.com |
| Mailing address | 90 Collins Street Level 21 Melbourne VIC 3000 Australia |
| Phone / Fax | 61 2 8003 3650 / 61 2 9225 5050 |
| Share registry | COMPUTERSHARE INVESTOR SERVICES PTY LIMITED |
Dividends
Amplia Therapeutics does not pay dividends.
Company Executives
As of Aug 2021, following are the company executives and directors listed on Amplia Therapeutics.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. John Lambert B.Sc., BSc (Hons), MRACI, C.Chem., Ph.D. | CEO, MD & Director | 55 | 379.19k |
| Mr. Jeff Carter | Chief Financial Officer | 62 | 117.3k |
| Dr. Mark Devlin B.Sc., Ph.D. | Chief Scientific Officer | ||
| Mr. Andrew John Cooke LLB, FAICS, MAICD, FGIA, FCIS | Company Sec. | 60 | |
| Dr. Frank Gelder | Founding Scientist | ||
| Dr. James A. Taylor | Trials Consultant | 59 | |
| Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR | Trials Consultant | 72 | |
| Dr. Benjamin M. Segal | Clinical Consultant | ||
| Dr. Frederick E. Reno | Toxicology Consultant |
Profitability and management effectiveness
Profit margin
-148.75%
Operating margin
-152.60%
Return on assets
-14.63%
Return on equity
-24.08%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Amplia Therapeutics is 22.47M and its enterprise value is 18.67M. The enterprise value to revenue ratio of ATX is 12.17.
The ATX's stocks Beta value is 0.42 making it 58% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Amplia Therapeutics (ATX)
Amplia Therapeutics (ASX:ATX) Frequently Asked Questions
1. What is Amplia Therapeutics's Stock Symbol?
Amplia Therapeutics trades on ASX under the ticker symbol "ATX".
2. What is Amplia Therapeutics's stock price today?
One share of ATX stock can currently be purchased for approximately $0.18.
3. How can I contact Amplia Therapeutics?
Amplia Therapeutics's mailing address is 90 Collins Street Level 21 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 2 8003 3650.
4. What is Amplia Therapeutics's official website?
The official website of Amplia Therapeutics is http://www.ampliatx.com.
5. Which share registry manages Amplia Therapeutics's stock?
Amplia Therapeutics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.